<table border="1" style="text-align:center"><tr><td><a href="https://finance.yahoo.com/quote/ZDGE">ZDGE</a></td><td>Zedge Inc Cl B</td><td style="background-color:lightgreen">0</td><td style="background-color:lightpink">0</td><td style="background-color:lightgrey">0</td><tr><td colspan="5" style="text-align:justify">Zedge, Inc. operates a digital publishing and content platform worldwide. Its platform enables consumers to personalize their mobile devices with ringtones, wallpapers, home screen app icons, widgets, and notification sounds. The company was incorporated in 2008 and is based in New York, New York.</td></tr></tr><tr><td><a href="https://finance.yahoo.com/quote/YCBD">YCBD</a></td><td>Cbdmd Inc</td><td style="background-color:lightgreen">0</td><td style="background-color:lightpink">0</td><td style="background-color:lightgrey">1</td><tr><td colspan="5" style="text-align:justify">cbdMD, Inc. produces and distributes various cannabidiol (CBD) products. It owns and operates consumer hemp-based CBD brands, such as cbdMD and Paw CBD. Its cbdMD brand products include CDB tinctures, gummies, topicals, capsules, bath bombs, bath salts, and sleep aids. The company also offers veterinarian-formulated products, including tinctures, chews, and topicals under the Paw CBD brand name. It distributes its products through its e-commerce Website, third party e-commerce sites, wholesalers, and various brick and mortar retailers in the <span style="background-color:lightgrey">United States</span>. The company was formerly known as Level Brands, Inc. and changed its name to cbdMD, Inc. in May 2019. cbdMD, Inc. was founded in 2015 and is headquartered in Charlotte, North Carolina.</td></tr></tr><tr><td><a href="https://finance.yahoo.com/quote/ZOM">ZOM</a></td><td>Zomedica Pharmaceuticals Corp</td><td style="background-color:lightgreen">0</td><td style="background-color:lightpink">6</td><td style="background-color:lightgrey">1</td><tr><td colspan="5" style="text-align:justify">Zomedica Corp., a development stage veterinary diagnostic and <span style="background-color:lightpink">pharmaceutical</span> company, engages in the discovery, development, and commercialization of <span style="background-color:lightpink">pharmaceuticals</span> for the companion pet. Its <span style="background-color:lightgrey">lead</span> drug product candidate is ZM-007, an oral suspension formulation of metronidazole for the treatment of acute diarrhea in small dog breeds and puppies. The company is also developing ZM-012, a tablet formulation of metronidazole targeting the treatment of acute diarrhea in <span style="background-color:lightpink">dogs</span>; ZM-006, a transdermal gel formulation of methimazole targeting hyperthyroidism in <span style="background-color:lightpink">cats</span>; and ZM-011, a transdermal gel formulation of fluoxetine for the treatment of feline behavioral disorders, such as inappropriate urination. It has a collaboration agreement with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of <span style="background-color:lightpink">cancer</span> in companion animals; and with Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica <span style="background-color:lightpink">Pharmaceuticals</span> Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.</td></tr></tr><tr><td><a href="https://finance.yahoo.com/quote/XTNT">XTNT</a></td><td>Xtant Medical Holdings Inc</td><td style="background-color:lightgreen">7</td><td style="background-color:lightpink">1</td><td style="background-color:lightgrey">1</td><tr><td colspan="5" style="text-align:justify">Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the <span style="background-color:lightgrey">United States</span> and internationally. Its biomaterial products include OsteoSponge that provides a <span style="background-color:lightgreen">natural</span> scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSponge SC that fills bony defects in the subchondral region of joints; OsteoSelect DBM Putty for osteoinductive bone growth; OsteoSelect PLUS DMB Putty for use as a bone void filler and bone graft substitute in the pelvis, extremities, and posterolateral spine; and OsteoWrap that wraps around non-union fractures to assist with <span style="background-color:lightgreen">fusion</span>, as well as used in conjunction with a hardware plate system. The company also provides OsteoSTX for posterolateral spine surgery applications, including scoliosis procedures; and 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone. In addition, it processes and distributes sports allografts for anterior and posterior cruciate ligament repairs, anterior cruciate ligament reconstruction, and meniscal repair; milled spinal allografts for cortical bone milled to desired shapes and dimensions; and traditional allografts for orthopedics, neurology, podiatry, oral/maxillofacial, genitourinary, and <span style="background-color:lightpink">plastic</span>/reconstructive applications. Further, the company offers Certex spinal fixation system; Spider cervical plating system; Axle Interspinous <span style="background-color:lightgreen">Fusion</span> System; Silex Sacroiliac joint <span style="background-color:lightgreen">fusion</span> system; Xpress minimally invasive pedicle screw system; and Fortex Pedicle screw system. Additionally, it provides Calix for cervical and thoracolumbar applications, Axle-X interspinous <span style="background-color:lightgreen">fusion</span> system, Irix-C cervical integrated <span style="background-color:lightgreen">fusion</span> system, and Irix-A Lumbar integrated <span style="background-color:lightgreen">fusion</span> system. The company was formerly known as Bacterin International Holdings, Inc. and changed its name to Xtant Medical Holdings, Inc. in July 2015. Xtant Medical Holdings, Inc. is headquartered in Belgrade, Montana.</td></tr></tr><tr><td><a href="https://finance.yahoo.com/quote/XXII">XXII</a></td><td>22nd Century Group Inc</td><td style="background-color:lightgreen">2</td><td style="background-color:lightpink">2</td><td style="background-color:lightgrey">7</td><tr><td colspan="5" style="text-align:justify">22nd Century Group, Inc., a <span style="background-color:lightgreen">plant</span> <span style="background-color:lightgrey">biotechnology</span> company, provides <span style="background-color:lightgrey">technology</span> that allows to alter the level of <span style="background-color:lightgrey">nicotine</span> and other nicotinic alkaloids in <span style="background-color:lightgrey">tobacco</span> plants, and cannabinoids in hemp/cannabis plants through genetic engineering and <span style="background-color:lightgreen">plant</span> breeding. The company offers SPECTRUM research <span style="background-color:lightpink">cigarettes</span> for use in independent clinical studies; and very low <span style="background-color:lightgrey">nicotine</span> content (VLNC) <span style="background-color:lightgrey">tobacco</span> <span style="background-color:lightpink">cigarettes</span> under the Moonlight and Moonlight Menthol brands. It is also involved in contract manufacturing business for third-party branded <span style="background-color:lightgrey">tobacco</span> products. The company has a strategic research and development agreement with Keygene N.V. to develop hemp/cannabis plants for medical, therapeutic, and agricultural uses, as well as for other applications. 22nd Century Group, Inc. was founded in 1998 and is headquartered in Williamsville, New York.</td></tr></tr></table>